Get the Stockscreener App
0.3529
2.76%
-0.01
Vyne Therapeutics Inc stock is traded at $0.3529, with a volume of 2.94M.
It is down -2.76% in the last 24 hours and down -80.06% over the past month.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
See More
Previous Close:
$0.3629
Open:
$0.3436
24h Volume:
2.94M
Relative Volume:
2.20
Market Cap:
$5.37M
Revenue:
$486.00K
Net Income/Loss:
$-28.43M
P/E Ratio:
-0.1252
EPS:
-2.8189
Net Cash Flow:
$-26.75M
1W Performance:
-75.83%
1M Performance:
-80.06%
6M Performance:
-84.98%
1Y Performance:
-80.61%
1-Day Range:
$0.3436
$0.365
1-Week Range:
$0.3403
$1.595
52-Week Range:
$0.3403
$4.30
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Name
Vyne Therapeutics Inc
Sector
Industry
Phone
800-775-7936
Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Compare VYNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
0.3529 | 6.09M | 486.00K | -28.43M | -26.75M | -2.8189 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | BTIG Research | Buy |
| Dec-06-21 | Resumed | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Stock (VYNE) Latest News
BTIG Research Downgrades VYNE Therapeutics (NASDAQ:VYNE) to Neutral - Defense World
Will earnings trigger a reversal in VYNE Therapeutics Inc.AI Triggered Buy Zone Forecast System - Newser
Real time pattern detection on VYNE Therapeutics Inc. stockAI Trading Suggestions With Accuracy Focus Released - metal.it
How to read the order book for VYNE Therapeutics Inc.Trading Watchlist with Real Time Filters - Newser
VYNE Therapeutics (NASDAQ:VYNE) Stock Rating Lowered by HC Wainwright - Defense World
Published on: 2025-07-31 20:14:07 - Newser
Does VYNE Therapeutics Inc. stock pay reliable dividendsCapital Secure Pattern Signal Analysis Sheet - Newser
Here's Why VYNE Therapeutics (NASDAQ:VYNE) Must Use Its Cash Wisely - Yahoo Finance
What are analysts’ price targets for VYNE Therapeutics Inc. in the next 12 monthsAdvanced Screener Alerts That Work - jammulinksnews.com
VYNE Therapeutics stock rating downgraded to Neutral by BTIG after trial miss - Investing.com Canada
Vyne Seeks Partner For Repibresib After Phase IIb Vitiligo Fail - insights.citeline.com
Gold Gains 1%; Wingstop Shares Spike Higher - Benzinga
VYNE’s vitiligo treatment fails primary endpoint in phase 2b trial - Investing.com Australia
VYNE’s vitiligo treatment fails primary endpoint in phase 2b trial By Investing.com - Investing.com India
H.C. Wainwright downgrades VYNE Therapeutics stock rating on vitiligo trial data - Investing.com Canada
US Stocks Edge Higher; Kraft Heinz Earnings Top Views - Benzinga
VYNE Therapeutics Ends Phase 2b Trial for Repibresib - TipRanks
VYNE Therapeutics stock falls after vitiligo trial fails to meet endpoints - Investing.com
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo - The Manila Times
VYNE's Vitiligo Drug Shows Mixed Results: 43% Improvement in High-Dose Group Despite Trial Miss - Stock Titan
VYNE Therapeutics (NASDAQ:VYNE) Shares Down 0.7% – Here’s What Happened - Defense World
What makes VYNE Therapeutics Inc. stock price move sharplyReal-Time Market Sentiment Tracking Gains Momentum - metal.it
Is VYNE Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideChart Risk Profile for Capital Preservation - Newser
Will breakout in VYNE Therapeutics Inc. lead to full recoveryBuy Point Strategy with Profit Protection - Newser
What is the dividend policy of VYNE Therapeutics Inc. stockBest Dividend Guidance For Fast Growth - jammulinksnews.com
What analysts say about VYNE Therapeutics Inc. stock outlookDaily Market Entry Strategy with Tools - Newser
VYNE Therapeutics Inc. Facing Inflection Point in Trend AnalysisEntry and Exit Strategy Optimizer Tool Tested - metal.it
Published on: 2025-07-29 03:11:42 - metal.it
How many analysts rate VYNE Therapeutics Inc. as a “Buy”Pre Market Trend Scanner With High Returns - jammulinksnews.com
Vyne Therapeutics: A Risky Bet On Upcoming Vitiligo Ph2b Readout (NASDAQ:VYNE) - Seeking Alpha
What institutional investors are buying VYNE Therapeutics Inc. stockInvest smarter with data-backed trading alerts - jammulinksnews.com
How does VYNE Therapeutics Inc. generate profit in a changing economyFree Investment Case Studies - jammulinksnews.com
What makes VYNE Therapeutics Inc. stock price move sharply Growth Projection Summary for Long-Term Investors - Newser
What analysts say about VYNE Therapeutics Inc. stock outlook Free Buy Alerts With Low Risk Confirmation - Newser
How volatile is VYNE Therapeutics Inc. stock compared to the marketCapitalize on market momentum for maximum gains - jammulinksnews.com
When is VYNE Therapeutics Inc. stock expected to show significant growthMassive stock growth - jammulinksnews.com
How strong is VYNE Therapeutics Inc. company’s balance sheetSuperior investment outcomes - jammulinksnews.com
How Resilient Is VYNE Therapeutics Inc. Stock During Economic DownturnsSafe High Return Entry Points - metal.it
How Efficient Is VYNE Therapeutics Inc. at Controlling Operating CostsFree Access to Community - Newser
How VYNE Therapeutics Inc. stock performs during market volatilityTrade Setup Builder with Custom Alerts - Newser
Vyne Therapeutics Inc Stock (VYNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):